KR101299320B1 - 초과산화물 억제제 효과를 갖는 프로부콜 및테트라졸릴알콕시-디히드로카르보스티릴 유도체를 함유하는조합 약물 - Google Patents

초과산화물 억제제 효과를 갖는 프로부콜 및테트라졸릴알콕시-디히드로카르보스티릴 유도체를 함유하는조합 약물 Download PDF

Info

Publication number
KR101299320B1
KR101299320B1 KR1020087008859A KR20087008859A KR101299320B1 KR 101299320 B1 KR101299320 B1 KR 101299320B1 KR 1020087008859 A KR1020087008859 A KR 1020087008859A KR 20087008859 A KR20087008859 A KR 20087008859A KR 101299320 B1 KR101299320 B1 KR 101299320B1
Authority
KR
South Korea
Prior art keywords
probucol
cilostazol
combination
delete delete
superoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087008859A
Other languages
English (en)
Korean (ko)
Other versions
KR20080049822A (ko
Inventor
기환 홍
도모히로 요시까와
Original Assignee
오츠카 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오츠카 세이야쿠 가부시키가이샤 filed Critical 오츠카 세이야쿠 가부시키가이샤
Publication of KR20080049822A publication Critical patent/KR20080049822A/ko
Application granted granted Critical
Publication of KR101299320B1 publication Critical patent/KR101299320B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020087008859A 2005-09-15 2006-09-14 초과산화물 억제제 효과를 갖는 프로부콜 및테트라졸릴알콕시-디히드로카르보스티릴 유도체를 함유하는조합 약물 Expired - Fee Related KR101299320B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71695405P 2005-09-15 2005-09-15
US60/716,954 2005-09-15
US76177506P 2006-01-25 2006-01-25
US60/761,775 2006-01-25
PCT/JP2006/318675 WO2007032557A1 (en) 2005-09-15 2006-09-14 Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects

Publications (2)

Publication Number Publication Date
KR20080049822A KR20080049822A (ko) 2008-06-04
KR101299320B1 true KR101299320B1 (ko) 2013-09-03

Family

ID=37420867

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087008859A Expired - Fee Related KR101299320B1 (ko) 2005-09-15 2006-09-14 초과산화물 억제제 효과를 갖는 프로부콜 및테트라졸릴알콕시-디히드로카르보스티릴 유도체를 함유하는조합 약물

Country Status (20)

Country Link
US (2) US8580818B2 (enExample)
EP (2) EP2275106A1 (enExample)
JP (2) JP5179354B2 (enExample)
KR (1) KR101299320B1 (enExample)
AR (1) AR057520A1 (enExample)
AU (1) AU2006289752B2 (enExample)
BR (1) BRPI0616223A2 (enExample)
CA (1) CA2620296C (enExample)
CY (1) CY1112716T1 (enExample)
DK (1) DK1942895T3 (enExample)
ES (1) ES2378896T3 (enExample)
IL (1) IL189751A0 (enExample)
MY (1) MY145787A (enExample)
NO (1) NO20081811L (enExample)
PL (1) PL1942895T3 (enExample)
PT (1) PT1942895E (enExample)
RU (1) RU2411945C2 (enExample)
SG (1) SG165379A1 (enExample)
TW (1) TWI372053B (enExample)
WO (1) WO2007032557A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065588A1 (es) * 2007-03-09 2009-06-17 Otsuka Pharma Co Ltd Un medicamento para tratar enfermedad pulmonar obstructiva cronica
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
CN120441542B (zh) * 2025-05-08 2025-09-30 安徽益普克医药科技发展有限公司 一种西洛他唑衍生物及其制备方法与用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024400A1 (en) * 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
US20040082608A1 (en) * 2002-10-23 2004-04-29 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPH04193836A (ja) * 1990-11-26 1992-07-13 Banyu Pharmaceut Co Ltd 抗高脂血症剤
JPH107590A (ja) 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
JP2001500875A (ja) 1996-09-18 2001-01-23 メルク エンド カンパニー インコーポレーテッド 心臓血管系疾患関連の危険性を減らす併用治療法
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
AU5965399A (en) 1998-10-12 2000-05-01 Andreas Bockelmann Pharmaceutically active composition
CA2406077C (en) 2000-04-10 2010-07-20 Nicholas J. Wald Formulation for the prevention of cardiovascular disease
US20020115728A1 (en) * 2000-09-05 2002-08-22 Roland Stocker Compositions and methods for treating cardiovascular disorders
CA2434436A1 (en) * 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003192573A (ja) * 2001-12-25 2003-07-09 Otsuka Pharmaceut Factory Inc 経口ゲル製剤
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
JP2005232059A (ja) * 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
PT1894576E (pt) 2005-06-08 2011-07-29 Kowa Co Novo agente redutor dos níveis de triglicéridos
JP4193836B2 (ja) 2005-10-24 2008-12-10 ブラザー工業株式会社 インク噴射装置の製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024400A1 (en) * 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
US20040082608A1 (en) * 2002-10-23 2004-04-29 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
The American Journal of Cardiology, vol.82, pp.144-147 (1998) *
The American Journal of Cardiology, vol.82, pp.144-147 (1998)*
The Journal of Pharmacology and Experimental Therapeutics, Vol. 313, No.2, pp.502-509 (2005) *
The Journal of Pharmacology and Experimental Therapeutics, Vol. 313, No.2, pp.502-509 (2005)*

Also Published As

Publication number Publication date
MY145787A (en) 2012-04-30
NO20081811L (no) 2008-04-14
KR20080049822A (ko) 2008-06-04
PT1942895E (pt) 2012-03-29
CA2620296C (en) 2013-10-22
JP2009508804A (ja) 2009-03-05
US8580818B2 (en) 2013-11-12
TW200744597A (en) 2007-12-16
AU2006289752A1 (en) 2007-03-22
EP1942895B1 (en) 2012-02-01
JP5603393B2 (ja) 2014-10-08
US20140045889A1 (en) 2014-02-13
ES2378896T3 (es) 2012-04-18
AU2006289752B2 (en) 2011-06-09
TWI372053B (en) 2012-09-11
BRPI0616223A2 (pt) 2011-06-14
WO2007032557A1 (en) 2007-03-22
PL1942895T3 (pl) 2012-07-31
JP5179354B2 (ja) 2013-04-10
CA2620296A1 (en) 2007-03-22
US20090176826A1 (en) 2009-07-09
DK1942895T3 (da) 2012-03-05
EP1942895A1 (en) 2008-07-16
SG165379A1 (en) 2010-10-28
EP2275106A1 (en) 2011-01-19
CY1112716T1 (el) 2016-02-10
IL189751A0 (en) 2008-12-29
JP2013014605A (ja) 2013-01-24
AR057520A1 (es) 2007-12-05
RU2008114512A (ru) 2009-10-20
HK1122996A1 (en) 2009-06-05
RU2411945C2 (ru) 2011-02-20

Similar Documents

Publication Publication Date Title
Liu et al. Mito‐TEMPO alleviates renal fibrosis by reducing inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress
Fink Ethyl pyruvate: a novel anti‐inflammatory agent
Peng et al. Dexmedetomidine post‐treatment attenuates cardiac ischaemia/reperfusion injury by inhibiting apoptosis through HIF‐1α signalling
Huang et al. Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells
Chen et al. Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system
Bravard et al. Inhibition of xanthine oxidase reduces hyperglycemia-induced oxidative stress and improves mitochondrial alterations in skeletal muscle of diabetic mice
Zhang et al. Protective Effects of Oroxylin A Against Doxorubicin‐Induced Cardiotoxicity via the Activation of Sirt1 in Mice
Morris et al. Reversible heart failure: toxins, tachycardiomyopathy and mitochondrial abnormalities
JP2023116697A (ja) 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法
B Flemming et al. Tapping into mitochondria to find novel targets for diabetes complications
Zhang et al. Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy
Klawitter et al. Cyclophilin D knockout protects the mouse kidney against cyclosporin A-induced oxidative stress
JP5603393B2 (ja) スーパーオキサイド抑制効果を有するプロブコールおよびテトラゾリルアルコキシ−ジヒドロカルボスチリル誘導体を含む併用薬
CN118001283A (zh) 用于预防及治疗糖尿病性肾病的包含腺苷衍生物的药学组合物
Yousif et al. Role of Ca2+/calmodulin‐dependent protein kinase II in development of vascular dysfunction in diabetic rats with hypertension
Mendizábal et al. Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones
WO2022048618A1 (en) Methods to treat inflammatory bowel disease
Tan et al. Cardioprotective time-window of Penehyclidine hydrochloride postconditioning: A rat study
HK1122996B (en) Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide suppressant effects
CN101267823A (zh) 具有超氧化物抑制作用的包含普罗布考和四唑基烷氧基-二氢喹诺酮衍生物的组合药物
JP5634985B2 (ja) インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物
WO2002085376A2 (en) A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
Swaminathan et al. The role of NADPH oxidase in diabetic kidney disease: Mechanisms, isoforms, and therapeutic opportunities
Zhang et al. Glaucocalyxin B ameliorates inflammatory injury in diabetic cardiomyopathy by inhibiting the NF-κB/NLRP3 pathway
Falah The role of the cdk5 pathway and NMDA receptor phosphorylation in neurodegeneration in hippocampal sclerosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160817

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160817